Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Candidiasis Pipeline Drugs Market Report Overview
Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti-fungal drugs.
The Candidiasis – drugs in development research report provides a comprehensive overview on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.
Key Targets in the Candidiasis Pipeline Drugs Market
The key targets in the Candidiasis pipeline drugs market are Ergosterol, Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, Cell Membrane, Bacterial Cell Membrane, Candida albicans Extent of Cell Elongation Protein 1, Chitin Synthase, GPI Anchored Wall Transfer Protein 1 among others.
Candidiasis Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Candidiasis Pipeline Drugs Market
The key mechanisms of action in the Candidiasis pipeline drugs market are Ergosterol Inhibitor, Lanosterol 14 Alpha Demethylase Inhibitor, 1,3 Beta Glucan Synthase Inhibitor, Cell Membrane Disruptor, Bacterial Cell Membrane Disruptor, Candida albicans Extent of Cell Elongation Protein 1 Inhbitor, Chitin Synthase Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, C-C Chemokine Receptor Type 1 Antagonist among others.
Candidiasis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Candidiasis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Candidiasis pipeline drugs market are Oral, Intravenous, Topical, Vaginal, Inhalational, Subcutaneous, Intradermal, Nasal, and Parenteral.
Candidiasis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Candidiasis Pipeline Drugs Market
The key molecule types in the Candidiasis pipeline drugs market are Small Molecule, Synthetic Peptide, Monoclonal Antibody, Recombinant Peptide, Cell Therapy, Conjugate Vaccine, Vaccine, Antibody, Biologic, Fusion Protein, Peptide, Polymer, Recombinant Protein.
Candidiasis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Candidiasis Pipeline Drugs Market
The major companies in the Candidiasis pipeline drugs market are Mycovia Pharmaceuticals Inc, Satellos, Bioscience Inc, Scynexis Inc, Destiny Pharma Plc, AbGenics Life Sciences Pvt Ltd, Cidara, Therapeutics Inc, General Biologicals Corp, Matinas BioPharma Holdings Inc, Pfizer Inc, Profem GmbH, Pulmonomy Inc among others.
Candidiasis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Candidiasis Pipeline Drugs Market Overview
| Key Targets | Ergosterol, Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, Cell Membrane, Bacterial Cell Membrane, Candida albicans Extent of Cell Elongation Protein 1, Chitin Synthase, and GPI Anchored Wall Transfer Protein 1 |
| Key Mechanisms of action | Ergosterol Inhibitor, Lanosterol 14 Alpha Demethylase Inhibitor, 1,3 Beta Glucan Synthase Inhibitor, Cell Membrane Disruptor, Bacterial Cell Membrane Disruptor, Candida albicans Extent of Cell Elongation Protein 1 Inhbitor, Chitin Synthase Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, and C-C Chemokine Receptor Type 1 |
| Key Routes of Administration | Oral, Intravenous, Topical, Vaginal, Inhalational, Subcutaneous, Intradermal, Nasal, and Parenteral |
| Key molecule types | Small Molecule, Synthetic Peptide, Monoclonal Antibody, Recombinant Peptide, Cell Therapy, Conjugate Vaccine, Vaccine, Antibody, Biologic, Fusion Protein, Peptide, Polymer, and Recombinant Protein |
| Major companies | Mycovia Pharmaceuticals Inc, Satellos, Bioscience Inc, Scynexis Inc, Destiny Pharma Plc, AbGenics Life Sciences Pvt Ltd, Cidara, Therapeutics Inc, General Biologicals Corp, Matinas BioPharma Holdings Inc, Pfizer Inc, Profem GmbH, and Pulmonomy Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis
- The pipeline guide reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Candidiasis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Candidiasis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Candidiasis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Candidiasis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Autoimmune Technologies LLC
Bakker Medical Srl
Beta Pharma Inc
Biokawthar Technologies SAS
Biomendics LLC
Biosergen AS
Cidara Therapeutics Inc
CSA Biotechnologies LLC
CSPC Pharmaceutical Group Ltd
Destiny Pharma Plc
Fox Chase Chemical Diversity Center Inc
FUJIFILM Toyama Chemical Co Ltd
General Biologicals Corp
Grupo Ferrer Internacional SA
Hennepin Life Sciences LLC
Knight Therapeutics Inc
Matinas BioPharma Holdings Inc
MicroRid Technologies Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Next Science Ltd
Nosopharm SAS
Novabiotics Ltd
Novartis AG
Oryn Therapeutics
Osel Inc
Pacgen Life Science Corp
Pfizer Inc
Profem GmbH
Pulmocide Ltd
Pulmonomy Inc
Purna Female Healthcare
REYON Pharmaceutical Co Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
Satellos Bioscience Inc
Scynexis Inc
Shaanxi Synthetic Pharmaceutical Co Ltd
Stadius Biopharma LLC
TGV Therapeutics
Toltec Pharmaceuticals LLC
Visterra Inc
Wellstat Vaccines LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Candidiasis pipeline drugs market?
The key targets in the Candidiasis pipeline drugs market are Ergosterol, Lanosterol 14 Alpha Demethylase, 1,3 Beta Glucan Synthase, Cell Membrane, Bacterial Cell Membrane, Candida albicans Extent of Cell Elongation Protein 1, Chitin Synthase, GPI Anchored Wall Transfer Protein 1.
-
What are the key mechanisms of action in the Candidiasis pipeline drugs market?
The key mechanisms of action in the Candidiasis pipeline drugs market are Ergosterol Inhibitor, Lanosterol 14 Alpha Demethylase Inhibitor, 1,3 Beta Glucan Synthase Inhibitor, Cell Membrane Disruptor, Bacterial Cell Membrane Disruptor, Candida albicans Extent of Cell Elongation Protein 1 Inhbitor, Chitin Synthase Inhibitor, GPI Anchored Wall Transfer Protein 1 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, C-C Chemokine Receptor Type 1.
-
What are the key routes of administration in the Candidiasis pipeline drugs market?
The key routes of administration in the Candidiasis pipeline drugs market are Oral, Intravenous, Topical, Vaginal, Inhalational, Subcutaneous, Intradermal, Nasal, and Parenteral.
-
What are the key molecule types in the Candidiasis pipeline drugs market?
The key molecule types in the Candidiasis pipeline drugs market are Small Molecule, Synthetic Peptide, Monoclonal Antibody, Recombinant Peptide, Cell Therapy, Conjugate Vaccine, Vaccine, Antibody, Biologic, Fusion Protein, Peptide, Polymer, Recombinant Protein.
-
What are the major companies in the Candidiasis pipeline drugs market?
The major companies in the Candidiasis pipeline drugs market are Mycovia Pharmaceuticals Inc, Satellos, Bioscience Inc, Scynexis Inc, Destiny Pharma Plc, AbGenics Life Sciences Pvt Ltd, Cidara, Therapeutics Inc, General Biologicals Corp, Matinas BioPharma Holdings Inc, Pfizer Inc, Profem GmbH,Pulmonomy Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports